Epidemiološke karakteristike COVID-19 u Republici Srpskoj: analiza prvih stotinu dana epidemije
Background/Aim: The World Health Organization (WHO) declared the spread of a novel disease COVID-19 as a pandemic on 11 March 2020. As of 12 June, there have been more than 7.4 million COVID-19 cases and more than 418,000 COVID-19 deaths globally. This paper represents epidemiological analysis of the first 100 days of COVID-19 epidemic in the Republic of Srpska.
Methods: Data of all COVID-19 cases confirmed in the Republic of Srpska between 4 March and 12 June were collected from epidemiological and laboratory testing reports obtained from the Public Health Institute of the Republic of Srpska. This cross-sectional analysis was carried out on a sample of 1,607 laboratory-confirmed COVID-19 cases, which included: summary of patient characteristics, examination of age distributions and sex ratios, calculation of case fatality and mortality rates, incidence rates analysis, epidemiological curve construction and subgroup analysis.
Results: Over 100 days after the first case was confirmed, the total number of infected patients in the Republic of Srpska rose to 1,607 (31,471 persons had been tested). As of 12 June, 69.9 % of those cases has recovered. During that period there were 117 confirmed deaths (average age 72 years; 60.7 % males; 86 % older than 60 years; 94 % with at least one comorbidity). The sex ratio among the confirmed cases was 0.95:1 (48.7 % men vs 51.3 % women). Infections were less common in persons below 20 years of age (7.3 % of all confirmed cases) and the majority of the affected persons were in the group 40-69 years of age. As much as 86 % of all death cases occurred in persons older than 60 years (average age 72 years) and 94 % of all death cases had at least one underlying condition (mostly cardiovascular diseases, 79.5 %).
Conclusion: Evaluating the clinical data of COVID-19 patients, finding the source of infection and studying the behavior of the disease is crucial for understanding of the pandemic.
2. WHO. Critical preparedness, readiness and response actions for COVID-19, interim guidance: World Health Organisation; 2020.
3. Adam D, Wu P, Wong JY, Lau EHY, Tsang TK, Cauchamez S, et al.. Clustering and superspreading potential of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections in Hong Kong. Res Square May 2020. Doi:10.21203/rs.3.rs-29548/v1
4. Al-Tawfic JA, Rodriguey Morales AJ. Super-spreading Events and Contribution to Transmission of MERS, SARS, and SARS-CoV-2 (COVID-19). J Hosp Infect . 2020 Jun;105(2):111-112.
5. WHO. Strategic preparedness and response plan. 2019 Novel Coronavirus (2019-nCoV) Geneva: WHO; 2020.
6. Ylli A, Wu YY , Burazeri G, Pirkle C , Sentell T. The lower COVID-19 related mortality and incidence rates in Eastern European countries are associated with delayed start of community circulation. medRxiv preprint doi: https://doi.org/10.1101/2020.05.22.20110148.this version posted May 26, 2020.
7. Pan A, Liu L, Wang C, Guo H, Hao X, Wang Q, et al. Association of Public Health Interventions With the Epidemiology of the COVID-19 Outbreak in Wuhan, China. JAMA. 2020. PMID: 32275295
8. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, Xiang H, Cheng Z, Xiong YJJ. Clinical characteristics of 138 hospitalized patients with 2019 novel Coronavirus–infected pneumonia in Wuhan, China. JAMA. 2020; 323(11):1061–9.
9. Shahriarirad R, Khodamoradi Z, Erfani A, Hosseinpour H , Ranjbar K, Yasaman Emami Y, et al. Super-spreading Events and Contribution to Transmission of MERS, SARS, and SARS-CoV-2 (COVID-19). J Hosp Infect 2020 Jun; 105(2):111-112.
10. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020;323 (13):1239-1242.
11. The Novel Coronavirus Pneumonia Emergency Response Epidemiology Team. Vital surveillances: the epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19)—China, 2020. China CDC Weekly. 2020;2:113-122.
12. Yang J, Zheng Y, Gou X, Pu K, Chen Z, Guo Q, et al. Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis. Int J Infect Dis 2020; 94: 91–95.
13. Hunter E, Price DA, Murphy E, van der Loeff IS, Baker KF, Lendrem D, et al. First experience of COVID-19 screening of health-care workers in England. Lancet. 2020 May 2; 395(10234):e77-e78
14. Maukayeva S, Karimova S. Epidemiologic character of COVID-19 in Kazakhstan: A preliminary report. North Clin Istanb 2020;7(3):210–213. doi: 10.14744/nci.2020.62443
15. Logar S. Care home facilities as new COVID-19 hotspots: Lombardy Region (Italy) case study. Arch Gerontol Geriatr. 2020 Jul-Aug; 89:104087. doi: 10.1016/j.archger.2020.104087
16. ECDC Public Health Emergency Team, Danis K, Fonteneau L, Georges S, Daniau C, Bernard-Stoecklin S, Domegan L, . High impact of COVID-19 in long-term care facilities, suggestion for monitoring in the EU/EEA, May 2020. Euro Surveill. 2020;25(22):pii=2000956. https://doi.org/10.2807/1560-7917.ES.2020.25.22.2000956
17. Covid-19-coronavirus-infographic-datapack [Online].
Available from: https://informationisbeautiful.net/visualizations/covid-19-coronavirus-infographic-datapack/